CIA
TPST icon

Capital Impact Advisors’s Tempest Therapeutics TPST Stock Holding History

Capital Impact Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3
Closed -$64K – 280
2015
Q3 		$64K Hold
3
– – 0.03% 257
2015
Q2 		$219K Hold
3
– – 0.1% 252
2015
Q1 		$263K Buy
+3
New +$399K 0.12% 251

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OH
Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Impact Advisors's TPST Position: Q4 2015 in Review

Capital Impact Advisors sold out of Tempest Therapeutics (TPST) in Q4 2015, closing a stake of 3 shares — an estimated $64K sold.

Capital Impact Advisors first reported a position in TPST in Q1 2015 and held it in 3 quarters. The position peaked at $263K in Q1 2015. 78 funds tracked by Wall St. Rank hold TPST as of Q4 2015.

  • Capital Impact Advisors reported no remaining Tempest Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 3 Tempest Therapeutics shares in Q4 2015, an estimated $64K.
  • Capital Impact Advisors first reported a position in Tempest Therapeutics in Q1 2015 and held it in 3 quarters.
  • Capital Impact Advisors's Tempest Therapeutics position peaked at $263K in Q1 2015.
  • 78 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2015.

Based on Capital Impact Advisors's 13F filing for Q4 2015, filed 11 Jan 2016.